Kuros Biosciences AG
SIX:KURN
Intrinsic Value
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of... [ Read More ]
The intrinsic value of one
KURN
stock under the Base Case scenario is
4.01
CHF.
Compared to the current market price of 6.86 CHF,
Kuros Biosciences AG
is
Overvalued by 42%.
KURN's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
KURN or that its price is influenced by factors unrelated to fundamentals.
Kuros Biosciences AG's market capitalization is 252.2m CHF.
KURN stock price is 6.86 CHF.
KURN stock (4.01 CHF) is 42% less than its price (6.86 CHF).
KURN. Open DCF Valuation
KURN stock (4.01 CHF) is 42% less than its price (6.86 CHF). Open Relative Valuation
KURN has upside potential of 192% compared to the average analyst price target.
Open Wall St Estimates
KURN's ROIC (Return on Invested Capital) has increased in the last 3 years from -17% to -16%, and is approaching profitability.
KURN's ROE (Return on Equity) has decreased in the last 3 years from -14% to -22%, and is approaching profitability.
KURN's Revenue has grown by an exceptional 87% over the past 12 months.
KURN's short-term assets (27m CHF) exceed its short-term liabilties (13m CHF).
KURN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -16%.
KURN has negative Operating Income for the last twelve months.
KURN has negative Net Income for the last twelve months.
KURN's ROE (Return on Equity) for the past 12 months is negative and is equal to -22%.
KURN has positive Gross Profit for the last twelve months.
KURN has negative Free Cash Flow for the last twelve months.
KURN's Revenue has been growing by an exceptional 103% per year for the last 3 years.
KURN has negative three-year average ROIC (Return on Invested Capital): -15%. The company is not efficient at using invested capital to generate operating income.
KURN has negative three-year average ROE (Return on Equity): -16%. The company is not efficient at transforming stockholders' equity into net income.
KURN's D/E (Debt to Equity) is very low and is equal to 0.03.
KURN's long-term assets (71m CHF) exceed its long-term liabilties (15m CHF).
KURN has negative Net Debt. This means that the company has more cash and short-term investments (14m CHF) than debt (2m CHF).
KURN's Altman Z-Score is very high and is equal to 6.32.
KURN doesn't generate enough operating income (-9m CHF) to safely cover interest payments on its debt (61k CHF).
Valuation Backtest
Kuros Biosciences AG
Run backtest to discover the historical profit from buying and selling
KURN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Kuros Biosciences AG
Balance Sheet Decomposition
Kuros Biosciences AG
| Current Assets | 27.2m |
| Cash & Short-Term Investments | 14.2m |
| Receivables | 7.6m |
| Other Current Assets | 5.4m |
| Non-Current Assets | 44.3m |
| PP&E | 2.6m |
| Intangibles | 41m |
| Other Non-Current Assets | 651k |
| Current Liabilities | 13.2m |
| Accounts Payable | 1.3m |
| Accrued Liabilities | 7.9m |
| Other Current Liabilities | 4m |
| Non-Current Liabilities | 1.6m |
| Long-Term Debt | 1.6m |
Earnings Waterfall
Kuros Biosciences AG
|
Revenue
|
33.6m
CHF
|
|
Cost of Revenue
|
-5.1m
CHF
|
|
Gross Profit
|
28.5m
CHF
|
|
Operating Expenses
|
-37.1m
CHF
|
|
Operating Income
|
-8.7m
CHF
|
|
Other Expenses
|
-5.1m
CHF
|
|
Net Income
|
-13.7m
CHF
|
Free Cash Flow Analysis
Kuros Biosciences AG
KURN Profitability Score
Profitability Due Diligence
Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
KURN Solvency Score
Solvency Due Diligence
Kuros Biosciences AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Kuros Biosciences AG's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KURN Price Targets Summary
Kuros Biosciences AG
According to Wall Street analysts, the average 1-year price target for
KURN
is 20.05 CHF
.
Shareholder Return
KURN Price
Kuros Biosciences AG
| Average Annual Return | -6.36% |
| Standard Deviation of Annual Returns | 10.72% |
| Max Drawdown | -62% |
| Market Capitalization | 252.2m CHF |
| Shares Outstanding | 36 604 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kuros Biosciences AG
Country
Industry
Market Cap
Dividend Yield
Description
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Contact
IPO
Employees
Officers
The intrinsic value of one
KURN
stock under the Base Case scenario is
4.01
CHF.
Compared to the current market price of 6.86 CHF,
Kuros Biosciences AG
is
Overvalued by 42%.
You don't have any saved screeners yet
